All News
2018 Predictions for Rheumatology
MedPage Today Editors surveyed a few rheumatologists for their major news predictions in 2018. Read on for predictions regarding drug pricing, biosimilars, autoimmunity and checkpoint inhibitors, and thrombotic events and JAK inhibition.
Read Article
The RheumNow Week in Review - 5 January 2018
Dr Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
Bone Marrow Edema May be Found in Normals, Athletes and Military Recruits
Rheumatology has published a study demonstrating that bone marrow edema as measured by magnetic resonance imaging (MRI) may be found in healthy people, but that such changes do not change with intense physical activity.
Read Article
MEASURE 3 Study - Anti-IL17 Benefits Persist in Spine Disease
Patients with ankylosing spondylitis (AS) have shown rapid and sustained responses to secukinumab (Cosentyx) in a third phase III trial that includes a higher dose of this anti-interleukin-17A monoclonal antibody, researchers reported.
Read Article
Therapeutic Update: 5 Questions on FDA Hearing for Tofacitinib in PsA (Best of 2017)
In this Therapeutic Update, Drs. Mease, Gibofsky and Cush answer five questions regarding the August 3rd FDA Arthritis Advisory Committee meeting that reviewed the potential approval of tofacitinib (Xeljanz) in patients with active psoriatic arthritis. The panel was nearly unanimous (10-1) in favor of the efficacy and safety profile of of tofacitinib, and similarly voted 10-1 to approve this drug for use in PsA. Final decisions on these recommendations from the AAC panel will be made at a later date by the FDA.
Read Article
The RheumNow Week in Review - 22 December 2017
Dr. Jack Cush reviews highlights and news from the past week on RheumNow.com.
Read Article
Cardiac Disturbances Increased in Spondyloarthritis
A prospective Swedish study between 2001–2009 found a higher risk of aortic regurgitation, pacemaker, AV block and atrial fibrillation in SpA, AS, uSpA and PsA patients.
Read Article
Frequency of Rheumatoid Knee Replacements Down in the Biologic Era
A time-series analysis of incident rheumatoid arthritis (RA) patients seen between 1996 and 2011 in the Danish National Patient Register shows that the incidence of hip (THR) and knee replacements (TKR) began to decrease after the introdution of biologic agents for RA in 2002.
Read Article
The RheumNow Week in Review - 15 December 2017
Dr. Jack Cush reviews the news from the past week on RheumNow.com. Subscribe to the podcast on iTunes and SoundCloud.com.
Read Article
2017 Update of Treat to Target Recommendations for SpA/PsA
A 2017 international committee of experts met to assess and revise its earlier 2012 recommendations regarding treating to target in patients with psoriatic arthritis (PsA) and axial peripheral spondyloarthritis (SpA).
Read Article
The RheumNow Week in Review - 8 December 2017
Dr. Jack Cush covers the news and journal articles published on RheumNow.comin the past week.
Read Article
Infliximab Does Not Increase Perioperative Infection
Staying on a TNF inhibitor (TNFi) throughout major surgery has generatlly been associated with higher rates of perioperative infection (https://buff.ly/2iBFVjp). On the other hand, discontinuation of the TNFi prior to surgery is associated with lower ra
Read Article
Rheumatology Year in Review
During 2017, the improvements and refinements seen during previous years in the treatment of rheumatoid arthritis have been extending to other conditions ranging from psoriatic arthritis to lupus and for both monoclonal antibodies and oral small molecule medications.
Read Article
Do JAK Inhibitors Increase the Risk of Venous Thromboembolic Events?
Drug Safety has published a systematic review of the FDA’s Adverse Event Reporting System (FAERS) and finds numerous reports of thromboembolic adverse events (AEs) associated with two currently marketed Janus kinase (JAK) inhibitors, tofacitinib (Xeljanz) and ruxolitinib (Jakafi).
Read Article
Ixekizumab (Taltz) FDA Approved for Psoriatic Arthritis
On Friday, December 1st, the FDA approved Lilly's drug Taltz (ixekizumab) for use in adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Taltz, an IL-17 inhibitor, has previously been approved for plaque psoriasis where it has shown high level PASI75 and PASI100 responses.
Read Article
The ACR17 RheumNow Week in Review - 1 December 2017
Dr Jack Cush reviews nighlights and news from the past 2 weeks on RheumNow.com. This week's report includes new drug approvals, disappointing ACR guidelines, Lyme & Zika, infertility, dermatomyositis skin outcomes and myositis-associated cancer testing.
Read Article
ACR Clinical Guidelines Flawed by Low Evidence
JAMA Internal Medicine has reported that recommendations and clinical practice guidelines from the American College of Rheumatology are often based on expert opinion, but lack rigorous (grade A) evidence to support many of their recommendations.
Read Article
ACR17 Good News – Ankylosing Spondylitis and Spondyloarthritis
The following is a collection of AS/SpA-specific mentions culled from RheumNow's coverage of the Annual ACR 2017 meeting in San Diego.
Read Article
The RheumNow Week in Review - 17 November 2017
Dr. Jack Cush reviews the news and highlights from the past week on RheumNow.com. This week he covers FDA warnings on gout drugs, steroid use in Australia, biosimilars lost savings and methotrexate hepatotoxicity in psoriatic arthritis (PsA).
Read Article
